Last mentioned: Mar 17, 2026
Wall Street Zen Downgrade
SABS and SSSS both receive Sell ratings from Wall Street Zen.
SAB-142 Clinical Progress
SAB Biotherapeutics continues enrollment for its Phase 1/2 trial in Type 1 Diabetes.
Strategic Pivot
Company shifts focus from infectious diseases to immunology and chronic conditions.
Wall Street Zen has issued 'Sell' ratings for both SAB Biotherapeutics and SURO Capital, signaling a shift in sentiment for high-risk biotech and venture-backed assets. These downgrades reflect growing analyst caution regarding clinical-stage development timelines and private equity valuation gaps in the 2026 market environment.
Wall Street Zen has downgraded SAB Biotherapeutics (SABS) and its investor SURO Capital (SSSS) to Sell ratings. The move signals increasing caution regarding SAB's clinical-stage polyclonal antibody platform and the broader venture-backed biotech ecosystem.